Thyroid Panel Research Articles

Dietary Supplement Use Among Older Dogs

Dietary supplement use among older dogs in the US is not well understood; we hypothesized it differs by health state.Dogs ≥ 5 yrs participated in a clinic visit (2016-2017). Veterinarians documented the dog's medical history, age & breed & completed a physical exam with blood draw for CBC/chemistry & thyroid analysis; medications & supplements were recorded if administered in the 60 days prior to study enrollment. Dogs were screened for enrollment in 6 categories based on standard criteria: healthy group (no known major medical conditions based on medical history, physical exam & blood work), atopic dermatitis (AD, atopy diagnosis and/or frequent licking or scratching), inflammatory bowel disease (IBD, chronic diarrhea with weight loss), hypothyroidism (HT, serum total T4 or thyroid panel consistent with hypothyroidism), calcium oxalate kidney or bladder urolithiasis (CO, confirmed by X-ray or extraction & analysis), and/or hip dysplasia (HD, history of unilateral or bilateral hip dysplasia based on X-ray).Dogs with ≥1 of the 5 target conditions formed the target group; multiple conditions were allowed.Patient records were reviewed after study completion to confirm accurate group classification. Supplements were categorized into ≥1 groups based on the ingredient list and/or guaranteed analysis: essential fatty acid (EFA), minerals, vitamins & other (i.e., prebiotics, probiotics, herbal, etc.).Information on supplement use was obtained from 992 dogs (5.0 to 20.8 yrs, median 9.4 yrs).982 (99%) had complete medical histories (484 healthy, 157 AD, 26IBD, 125 HT,58 CO, 95 HD; 58 dogs had ≥1 target condition).Of the 982 dogs, 193 dogs (19.7%) or 1 out of 5 dogs used any supplements. Use of any supplements by group was 15.9% (1 out of 7) among the healthy group and 36.1% (1 out of 3) among the target group (19.7% AD, 50.0% IBD, 25.8% HT, 10.7% CO, 35.4% HD). Of supplement-using dogs the highest number of supplements reported for any one dog was 7 and the lowest was 1. Among supplement-using dogs, on avg. the target group used a greater number of supplements containing EFA, minerals, vitamins and/or other ingredients than healthy dogs. Among supplement-using dogs, the IBD group used on avg. the most supplements (avg. 1.8 supplements/dog), followed by the HD group (avg. 1.6 supplements/dog) and healthy dogs (avg. 1.4 supplements/dog). HD dogs used the most supplements containing EFA (avg. 0.7 supplements/dog). CO dogs used the greatest number of mineral-containing supplements (avg. 0.5 supplements/dog) and vitamin-containing supplements (avg. 0.7 supplements/dog), and IBD dogs used the most other supplements (avg. 1.2 supplements/dog). Use of prebiotic, probiotic or CBD supplements was infrequent (less than 7% of all supplement-using dogs). Supplement use is common among older dogs and varies by health state (11-50%).Among supplement-using older dogs, those with AD, IBD, HT, and/or HD consume more supplements on avg. thanhealthy older dogs.The IBD & HD groups were highest in both prevalence of any supplement use & avg. number of supplements per dog.Of all older dogs included in this survey, nearly 20% used any supplements & of those, 12% used nutrient-containing supplements (EFA, vitamins, and/or minerals).Supplements may be important contributors to total daily nutrient intake in older dogs.

Thyroid panel reference intervals in healthy children and adolescents: A Spanish cohort

ObjectivesIn children, thyroid hormones are essential for correct physical and neurological development. The recommended process for defining reference intervals (RIs) is the direct approach; however, indirect methods are an effective alternative. This study aimed to explore age- and sex-dependent relationships between serum concentrations of thyroid hormones in a large population-based cohort of healthy Spanish Caucasian children and calculate RIs. Material and MethodsResults of serum thyroid-stimulating hormone (TSH) and free thyroxine (fT4) were collected from laboratory data of N (TSH = 23201; fT4 = 20728) patients aged 1 month − 15 years. These results were validated with a prospective study.Analyses of serum concentrations of TSH and fT4 were performed on ARCHITECT i2000 (Abbott Diagnostics, US). Percentiles (2.5th to 97.5th) were determined for each variable and taken as the RI. ResultsNo difference was found between serum TSH concentrations in male and female children of all age groups. A difference between serum fT4 concentrations in males and females and an age-dependent correlation for both sexes were found. ConclusionThere is very little consensus on RIs in children. Our data confirm it is possible to use data mining techniques to calculate reliable and clinically useful RIs.

Sources of variation and establishment of Russian reference intervals for major hormones and tumor markers

A multicenter study was organized to explore sources of variation (SVs) of reference values (RVs) for 22 major immunochemistry analytes and to determine reference intervals (RIs) for the Russian population. According to IFCC Committee on Reference Intervals and Decision Limits (C-RIDL) protocol, 758 healthy volunteers were recruited in St. Petersburg, Moscow, and Yekaterinburg. Serum samples were tested for five tumor markers, 17 hormones and related tests by Beckman Coulter's UniCel DxI 800 immunochemistry analyzer. SVs were explored using multiple regression analysis and ANOVA. Standard deviation ratio (SDR) of 0.4 was used as primary guide for partitioning RIs by gender and age. SDR for between-city difference was <0.4 for all analytes. Secondary exclusion of individuals was done under the following conditions: for female sex-hormones, those with contraceptives (8%); for CA19-9, those supposed to have negative Lewis blood-group (10.5% males and 11.3% females); for insulin, those with BMI≥28 kg/m2 (31%); for the thyroid panel, those with anti-thyroid antibodies (10.3% males; 24.5% females), for CEA those with smoking habit (30% males and 16% females). Gender-specific RIs were required for all analytes except CA19-9, CA15-3, thyroid-related tests, parathyroid hormone, and insulin. Age-specific RIs were required for alpha-fetoprotein, CEA, all sex-hormones for females, FSH and progesterone for both sexes. RIs were generally derived by parametric method after Gaussian transformation using modified Box-Cox formula. Exceptions were growth hormone, estradiol for females in postmenopause, and progesterone for females in premenopause, for which nonparametric method was required due to bimodal distribution and/or insufficient detection limit. RIs for major hormones and tumor markers specific for the Russian population were derived based on the up-to-date internationally harmonized protocol by careful consideration of analyte-specific SVs.

Canine Adult-Onset Hypothyroidism: Prevalence, Clinical and Laboratory Findings with Special Reference to Therapeutic Approach

Hypothyroidism is one of the most common endocrinopathies in dogs, it is defined as a decrease in production of thyroid hormones. Hypothyroidism results in vague clinical of signs but metabolic and dermatological signs are the most reported manifestations. This investigation aimed to study canine hypothyroidism in terms of clinical, haemato- biochemical, and thyroid panel alterations and evaluate response to treatment in adult onset hypothyroidism in dogs’ cosmopolitan in Cairo and Giza governorates. To crude determination of disease in dog cosmopolitan in Cairo and Giza governorates, multicenter study was conducted. In the period from December-2019 to May-2020, 220 dogs with various dermatologic signs represented to different clinics, after ruling out other causes, 40 with signs consistent with hypothyroidism were subjected to initial screening for hypothyroidism using TT4. Only 15 dogs showed decrease in TT4 and these dogs were further investigated, additional 8 clinically healthy dogs enrolled as control group. Blood sample was taken from both hypothyroid dogs [N=15] and control dogs [N=8] for hematology analysis, TT4, fT4, TSH. Cholesterol, ALT and ALP. Diseased group [15 dogs] were treated with levothyroxine and re-evaluated after 1-month period. Overall prevalence of hypothyroidism in this investigation was 7.5 percent. Significant decrease in RBCs, PCV, TT4 and fT4 along with non-significant increase in TSH and cholesterol were recorded in hypothyroid patients compared to control group. Treatment with levothyroxine caused thyroid hormones to be within normal reference range. The Prevalence of hypothyroidism in studied cases in this investigation was 7.5 % and is similar to the reported prevalence; diagnosis of hypothyroidism should be relying on combination of clinical and laboratory data. Usage of human levothyroxine can successfully manage caninehypothyroidism.

Abstract 13743: A Tale of Syncope, Prolonged QT and ICD

Introduction: Long QT syndrome (LQTS) was first described in the 1960s. It manifests clinically as syncope, cardiac arrest or sudden cardiac death. LQTS can be caused by 15 different genes. These mutations lead to action potential prolongation by causing impaired repolarizing currents. Case Discussion: A 29-year-old previously healthy Caucasian woman was admitted after recurrent episodes of syncope that happened within 1-month prior to the presentation. She was hemodynamically stable with normal vitals. Her ECG showed normal sinus rhythm with corrected QT (QTc) of 598ms. In the ED, she suffered an episode of sustained monomorphic ventricular tachycardia (VT) and underwent cardioversion. She was started on amiodarone infusion. Serial ECGs showed prolonged QTc. She had another episode of pulseless VT that terminated without defibrillation. She was transferred to our facility for further care. Her family history was significant for paternal aunt who had died unexpectedly at the age of 39. All her lab work including electrolytes, thyroid panel, cardiac enzymes, inflammatory markers and extended drug screen was unrevealing. Transthoracic echocardiogram showed normal biventricular size and function. Decision making: She was started on propranolol for possible LQTS. Cardiac MR did not show any evidence of structural abnormalities. Genetic panel was sent. Since myocarditis or familial LQTS could not be ruled out, we proceeded with implantable cardioverter defibrillator (ICD) implantation for secondary prevention. She was discharged home on nadolol. Conclusion: In the absence of genetic information, LQTS can be diagnosed in symptomatic patients with QTc &gt;480msec on serial ECGs after excluding secondary causes. Schwartz score comprising of ECG findings, symptoms, clinical &amp; family history is diagnostic when greater than 3.5. Beta-blockers are indicated in all patients with a clinical diagnosis. Patients must avoid any QT prolonging agents and strenuous exercise. An ICD is indicated in patients who suffered cardiac arrest. ICD may also be considered for primary prevention in high risk patients.

Impact of clinical pharmacist-led diabetes management clinic on health outcomes at an academic hospital in Riyadh, Saudi Arabia: A prospective cohort study

BackgroundDiabetes prevalence is estimated to reach 20.6% by 2030. Studies have illustrated main reasons for uncontrolled patients and concluded: low level of awareness, limited access to healthcare providers, and lack of cooperation between different disciplines. The role of pharmacists has been proven to improve patient-related outcomes, including an improvement in HgA1C readings between 0.54% and 1.6%. ObjectivesThis study was conducted to evaluate diabetes-related health outcomes in a pharmacist-led diabetes clinic in terms of HgbA1C level, guideline-recommended routine screenings, medication adherence, and biomarkers of other comorbidities. MethodA prospective cohort study conducted from August 2017 until July 2018 at an academic hospital. The pharmacist-led diabetes clinic was providing the service for a half-day per week. The study included all adult diabetic patients referred to the pharmacist-led clinic and had -at least- three 3-month apart follow-up visits with no exclusions. The baseline assessments for patients receiving routine diabetic care was performed using HgbA1C level, blood pressure, lipid and thyroid panel, eye and foot examinations, preventive measures, and adherence. The baseline results were compared to the follow-up results thereafter. A descriptive analysis was used to report the differences between intervals. Main outcome measure: (a) Reduction in HgbA1c levels, (b) intervention made by clinical pharmacists in an outpatient setting. ResultThe study included thirty-five patients. The mean ± SD age was 56 ± 10 years old. At baseline, mean HgbA1C was 9.5% ± 1.3%. HgbA1C was ≥10% for 13 patients. Albuminuria was never previously assessed for 14 patients. Twenty percent were receiving incorrect dose compared to the guideline-recommended statin therapy. By the end of study, mean HgbA1C had significantly improved to be 8.3% ± 1.4% (p = 0.0004). Nine patients achieved their HgbA1C goal of <7%. All patients were assessed for albuminuria, and managed accordingly. Thirty-two patients were eligible to receive statin therapy, and prescribed appropriate doses. Additionally, peripheral neuropathy was assessed for all cohort, and seven patients received recommended vaccinations. ConclusionInvolving clinical pharmacists in diabetes management clinic can provide valuable services, help patients to adhere to the therapeutic plans, and assist physicians to achieve better treatment outcomes.

The Effects of Antiepileptic Medications on Lipid Profile, Thyroid Panel, and Vitamin Level.

Background: Conventional antiepileptic drugs (AEDs) have been used for many years to treat epilepsy, and physicians are generally familiar with their side-effect profiles and potential drug interactions. However, AEDs affect patient vitamin and mineral levels in a manner that is not well understood. The goal of this study was to determine the relationship between AEDs and patient vitamins and mineral levels.Materials and methods: We conducted a retrospective analysis of liver enzyme levels, thyroid hormone levels, lipid profiles, and vitamin values (e.g., B12 and folic acid) in patients treated with carbamazepine, valproic acid, or levetiracetam at our institution. Patients were included in the study if their medical data included total cholesterol, triglyceride levels, low-density lipoprotein (LDL), and high-density lipoprotein (HDL) levels obtained on follow-up at least three months after the start of antiepileptic treatment with carbamazepine, valproic acid, or levetiracetam. Patients were grouped according to the antiepileptic drug used. We analyzed liver thyroid function tests, lipid profiles, levels of B12, and folic acid levels using laboratory test results and compared the findings from each group.Results: Carbamazepine, valproic acid, and levetiracetam did not change the levels of liver enzymes such as aspartate transaminase and alanine aminotransferase (p values respectively: .802, .094). Cholesterol and LDL levels were lower in patients using carbamazepine (p values respectively: .005, .005), and no significant difference was observed for HDL and triglyceride levels (p values respectively: .400, .091). While thyroid-stimulating hormone levels were significantly higher in patients on medication than the control group (p=.007), the levels were still within reference ranges. No significant difference was found between tri-iodothyronine and thyroxine levels (p values respectively: .065, .053). The levels of B12 and folic acid were observed to be high in the group using carbamazepine (p values respectively: .049, .004).Conclusion: Valproic acid and carbamazepine do not induce a significant increase in liver enzymes compared to levetiracetam, a new-generation antiepileptic medication, and they had no impact on lipoproteins such as HDL that are protective against coronary artery disease. These medications do not affect the levels of thyroid hormones in comparison to levetiracetam and the control group. Although carbamazepine and valproic acid are metabolized in the liver, liver enzyme monitoring is required; they have only affected liver enzyme values as much as levetiracetam and the control group.

Hashimoto encephalopathy induced by coronavirus

Background: Multiple factors can induce thyroid disease. The mechanism is not precise; a possible mimicry effect in the thyroid tissue could be the cause. Encephalopathy could be one manifestation of this thyroid disorder, but its mechanism is not well understood. There is a lack of data showing coronavirus as a possible cause of Hashimoto encephalopathy. Case Report: A 34-year-old obese Hispanic female was brought to our emergency department due to acute “Behavioral changes”. Her family noted her anxiety with repetitive head movement.; the patient presented with psychotic behavior, reporting family members were killed (The same that brought her), having auditory hallucinations; the family could not precisely predict the duration of this behavior. Her history includes asthma (never intubated, not on steroids), morbid obesity, galactorrhea, and extensive HTN and DM. She denied chest pain, palpitations, nausea, vomit, fever, malaise, recent flu-like symptoms. No abnormality in the physical examination was noted except for repetitive head movement; due to her acute mental status changes and lactic acidosis, she was admitted under critical care service. During her admission, the TSH/T3/ T4: 47.10/34/0.15, Antimicrosomal Ab and Coronavirus PCR were positive (Table1); CXR: No acute pathology, CT Head: Unremarkable, ultrasound neck showed Enlarged heterogeneous thyroid gland, which limits evaluation of underlying parenchyma; no measurable demonstrated solid, cystic or complex nodule (Figure 1). MRI head showed no pituitary adenoma. The patient was started on levothyroxine initially IV then transitioned to 200 mcg PO, and received ceftriaxone, dexamethasone, enoxaparin (As prophylaxis) for C19; after thyroid replacement was initiated; the patient started improving mental status drastically, she was transferred to the medical floor, later improved to baseline, and then was discharged. As an outpatient, the repeated thyroid panel showed normal values, and mental status was status as her baseline previous to her admission. Conclusion: Our case report describes a case of Hashimoto encephalopathy induced by SARS-CoV2 virus. Besides reports relating this thyroiditis with viral other viral entities, there is no data about this thyroid disorder in the 2020 pandemic.

Prognostic role of T3/T4 ratio in metastatic renal cell carcinoma (mRCC): Preliminary results of the threeFOUR multicenter study (Meet-Uro 14).

e17093 Background: Thyroid hormones metabolism can be altered in patients (pts) with chronic diseases and/or undergoing cancer treatments. The prognostic role of T3/T4 ratio has been investigated in metastatic colorectal cancer pts in whom a high T3/T4 ratio predicted longer survival. No data are available in mRCC. Methods: We retrospectively reviewed the clinical charts of pts with mRCC treated in first line for metastatic disease at 8 Italian Oncology Units before March 2017, having at least one response assessment and baseline complete thyroid panel data available. T3/T4 was calculated as the ratio of the two value of hormones and categorized in tertiles. Results: We identified 96 pts, median age 62 years (range 27-82), 72% males. Sunitinib wad administered in 56% of pts, pazopanib in 38%, nivolumab and ipilimumab in 6%. According to Heng Score, 33% of the pts were at favorable risk, 58% at intermediate risk, 9% at poor risk. With a median follow-up time of 42.8 months, median PFS was 24.8 months, estimated median OS was 71.6 months. Tertile distribution of patients was 36.4% in the high, 29.1% in the medium and 34.5% in the low subgroup. A baseline high tertile value (≥ 0.35) predicted longer PFS (39.4 vs 21.8 1vs 4.5 months, p = 0.01), while median OS has not been reached in the three tertiles, with survival at 24 months being 69.7%, 82.1% and 91.4%, respectively in the low, medium, high group (p = ns). The high T3/T4 ratio is also strongly associated with the chance to achieve a partial or complete response (42.8% vs 39.9% vs 21%, X squared test, p &lt; 0.001). Heng prognostic model retained its prognostic role in this cohort (median OS was 77.1 vs 48.4 vs 22.3 months, p &lt; 0.001, respectively for favorable, intermediate or poor risk group) and also predicted PFS (median PFS 38.2 vs 17.2 vs 8.4 months, p = 0.004). Baseline NLR ≥ 3 predicted shorter OS (46.5 vs 77.1 months, p = 0.02) in the whole group. Conclusions: In our retrospective multicenter experience, a high T3/T4 ratio was associated with longer PFS and a higher probability to respond to the treatment. Median OS had not been reached for all the subgroups, probably due to a favorable patients selection. A longer follow-up is needed to validate the prognostic value of T3/T4 ratio in this cohort.

SUN-691 Type 2 Diabetes Management in the Context of Smith-Magenis Syndrome: Case Report

Background: Smith-Magenis syndrome (SMS) is a rare condition caused by microdeletion chromosome 17p11.2 via RAI1 gene mutations, causing disrupted circadian sleep-wake patterns. Characteristic behaviors include: sleep disturbance, anxiety, maladaptive habits with self-injury (biting, picking, self-hugging, page-flipping) and outbursts. Characteristic features include: craniofacial abnormalities, short stature, 2/3 toe syndactyly, scoliosis, cardiac and genitourinary defects, hypotonia, peripheral neuropathy, epilepsy, childhood-onset truncal obesity, toileting difficulties. Management of adults with SMS span multiple disciplines: otolaryngology, audiology, ophthalmology, assessments of scoliosis, seizures, familial psychosocial health, sleep and behavioral changes with each medication. Annual assessments include: fasting lipids, thyroid panel, screening urinalysis. Patients should receive standard treatment for comorbid endocrine conditions, classically: hypercholesterolemia, hypothyroidism, growth hormone deficiency.Clinical Case: 49-year-old Hispanic female with history of SMS who presented to endocrinology for type 2 diabetes mellitus (T2DM) management. Past medical history includes T2DM with peripheral neuropathy, hypertension, hypercholesterolemia, intellectual disability, anxiety, recurrent genitourinary infections, sleep apnea. Physical exam is remarkable for macroglossia, truncal obesity, scoliosis, extremity excoriations evident of skin picking and xerosis, syndactyly of 2nd-3rd toes. Patient exhibited maladaptive behaviors like page-flipping, self-hugging, tantrums. Over the past 3 years, BMI remained in the obese range (>30 kg/m2) and A1c fluctuated from 7.0 to 10.6% averaging 8.8% (<5.7%). Patient is currently managed on insulin glargine, pioglitazone and liraglutide. She did not tolerate metformin due to dose-dependent diarrhea. Patient’s mother chose against SGLT2 inhibitors due to diminished genitourinary hygiene. T2DM management was complicated by patient behaviors, including nocturnal consumption of fructose-containing food and beverages, exercise intolerance, and associated caregiver fatigue.Conclusion: This case describes a patient managed for metabolic dysfunction in conjunction with a rare microdeletion disorder causing neurobehavioral disturbance with disrupted circadian sleep-wake patterns. The most difficult aspects of diabetes management included difficulty implementing lifestyle modifications to control the patient’s hyperglycemia.

Abstract P359: Assessment of Household Salt Types, Iodine Intake, and Iodine Status in 2019-2020 NHANES

Background: Iodine is an essential nutrient required for normal thyroid function in all age groups as well as healthy fetal, infant, and child development and growth. Because iodine levels in most foods are low, iodine usually must be provided through dietary supplements or fortified foods (such as salt). In recent NHANES cycles, sub-optimal iodine status has been observed in some U.S. populations, most notably pregnant women. Recent health campaigns have emphasized consuming less sodium and have focused on the primary source of the excess sodium in the U.S. diet: commercially prepared foods, most of which are made with non-iodized salt. Also, recent secular trends towards less home cooking and more use of non-iodized table salts may be contributing to relatively low usage of iodized salt, which was estimated in 2014 to comprise only half of retail salt sales. Therefore, for individuals who also limit their home use of salt in food preparation or at the table, an unintended consequence may be a decline in iodine intake. Population-level data thus are needed on the relative contributions of various foods to iodine intake in relation to iodine status markers, to characterize population groups at risk and develop guidance on appropriate dietary and supplementation strategies. Objective: Describe new measures of iodine intake and iodine status added into NHANES 2019-20, which is a nationally representative survey of the U.S. population. Methods: Iodine intake is being assessed through a questionnaire about household salt types (such as iodized salt or sea salt) and measured iodine content of household iodized salt, as well as individual 24-hour dietary recalls and use of iodine containing dietary supplements. This will be the first time NHANES will estimate dietary iodine intake using a newly developed USDA Special Interest Database on Iodine Content of Foods. Biomarkers include a thyroid panel (including thyroglobulin), inhibitors of iodine uptake in the thyroid (e.g., perchlorates), and urinary iodine concentration. Conclusions: The upcoming NHANES cycle will yield novel data on U.S. population coverage of household iodized salt, as well as individual thyroid and iodine status in relation to dietary iodine intake. Groups at risk from increased physiologic need or dietary preferences that limit iodine sources will be identified. A key tool in undertaking this work will be a new food composition database on the iodine content of U.S. foods. Clarification of key sources of iodine in the U.S. diet will be important in developing dietary guidance.

The “slightly” abnormal thyroid test: What is the pediatrician to do?

Thyroid disorders are common in pediatrics. Tests of thyroid function are widely available and frequently ordered in the pediatric healthcare setting. This is sometimes driven by common signs or symptoms of thyroid disease. All too often, it is driven by patients and their parents requesting thyroid tests for nonspecific symptoms, such as fatigue, obesity or family history of thyroid disease. The decision to order thyroid tests, as well as which test(s) of thyroid function to order, deserves careful thought rather than a reflexive "thyroid panel" for every patient. Thyroid stimulating hormone (TSH) is the single most appropriate test of thyroid function when screening a pediatric or adolescent for thyroid disorders. Adding more tests only increases the likelihood that a minor (and often insignificant) abnormality will be found. These incidental abnormalities can create anxiety for the parent and child, and usually results in additional testing, referral to a pediatric endocrinologist, and further expense. This review will aim to guide the pediatric primary care provider on the choice of appropriate screening test(s) for acquired thyroid dysfunction in children and adolescents, as well as the proper interpretation of the test(s). Emphasis will be placed on the "slightly" abnormal thyroid screening test. Specific thyroid tests to be reviewed include TSH, (free) T4, (free) T3, and thyroid antibodies. Finally, this review will aim to guide decisions on follow-up, additional testing, and reasons for referral to a pediatric endocrinologist. Congenital hypothyroidism, including abnormalities on state newborn screening, will not be discussed.

Optimization of the thyroid panel for diagnostic purposes: Thyrotropin cut-off values for the reflex addition of free thyroxine

Background-aimMeasurement of serum thyrotropin is currently the recommended test for the screening of thyroid dysfunction, while serum free thyroxine is kept as a reflex test. In our laboratory, the strategy followed in adult individuals from Primary Care includes a ‘safety margin’ for requests with a thyrotropin ≤1.0 or ≥4.0 mIU/L (normal: 0.35–4.95 mIU/L).Our aim was to optimize the thyrotropin cut-off values for the addition of free thyroxine and, based on these cut-offs, to retrospectively analyze avoidable free thyroxine measurements and possible adverse clinical consequences. MethodsRetrospective observational study performed in a tertiary care hospital between 2013 and 2018. We considered all laboratory requests for screening of thyroid dysfunction (TD) in adult patients from Primary Care. Requests from patients with a previous diagnosis of thyroid disease or pregnant women were excluded.Different receiver operating characteristic (ROC) curves were performed and the obtained thyrotropin cut-off values were compared. Economic savings were assessed considering the current cost of free thyroxin assays in our laboratory. ResultsFrom a total of 554,529 TD protocols included, 119,504 requests had free thyroxine added.From the ROC curve that enables ≥95% of abnormal free thyroxine results to be detected, the thyrotropin values obtained were ≥4.58 mIU/L and ≤0.94 mIU/L. These thyrotropin cut-off values would lead to a saving of 22.7% of annual free thyroxine measurements without adverse clinical consequences. DiscussionSetting optimized thyrotropin cutoffs for reflex testing of free thyroxine would reduce the need for this test. Clinical laboratories need to offer not only true results, but also become the cornerstone in the optimization of resources.

Thyroid Function and Nutrient Status in the Athlete.

Thyroid disease is common in the general population, especially in women, and also may be prevalent among athletes. Autoimmune disorders are the most common cause of thyroid disorders in countries with iodine-fortification programs; however, thyroid dysfunction can be brought on by nutritional factors, including insufficient energy intake and iodine, selenium, iron, and vitamin D deficiency. Additionally, strenuous exercise may be associated with transient alterations in thyroid hormones. While the development of thyroid related disorders has the potential to impact health and peak performance, typical clinical manifestations are highly variable, lack specificity, and are frequently confused with other health problems. The assessment process should focus on anthropometric changes, biochemical tests (thyroid panel), personal and family history, examination for appropriate signs and symptoms, and diet and environmental assessment that includes adequacy of energy, iodine, iron, selenium, and vitamin D intake/status along with excess stress and exposure to environmental contaminants and dietary goitrogens.

Трудный пациент: overlap-синдром, паранеопластический синдром или случайная полиморбидность?

Objective: to describe a clinical case of CRST syndrome in combination with an oncological disease. Materials and methods. Patient S., 64 years old, complained of dizziness, stiffness in the hands, numbness of fingers, loss of appetite. After a thorough questioning and examination, systemic scleroderma was suspected and an additional examination was prescribed, which included routine clinical and biochemical tests, a "thyroid panel", rheumatological parameters, tumor markers, chest x-ray, ultrasound of the abdominal cavity, thyroid ultrasound, electrocardiography, echo gastroscopy. Results: Based on the examination data, the diagnosis was made of adenocarcinoma of the antrum of the stomach, as well as limited scleroderma (CREST syndrome) in combination with chronic autoimmune thyroiditis (СAIT). The course of the disease almost completely fits into the CREST syndrome, but there was no confirmation of esophageal dysfunction or esophagitis (in this case, the term CRST syndrome is sometimes used). The rest of the limited version of scleroderma was beyond doubt. Cases when CAIT accompanied systemic lupus erythematosus, systemic scleroderma, Sjogren's syndrome, mixed connective tissue diseases, etc., have not only been described, but also studied for overlap conditions - overlap syndromes. Conclusion. The pathogenetic mechanisms of the association of various autoimmune diseases are not completely clear; it is assumed that the key role in the formation of polyautoimmunity is played by defects of the immune system associated with polymorphism of various genes, in combination with environmental factors and hormonal disorders. And the detection of an oncological process does not look random: because of autoimmunity, an aberrant immune response, or the use of immunomodulatory drugs, many of the rheumatic diseases seem to increase the risk of neoplasia Key words: gastric adenocarcinoma, CREST-syndrome, limited scleroderma, chronic autoimmune thyroiditis, overlap-syndrome, rare disease, etiology, diagnostic research, paraneoplastic syndrome, methodology of diagnosis.

Iodide Transporters in the Endometrium: A Potential Diagnostic Marker for Women with Recurrent Pregnancy Failures

Objective: The element iodine is an essential nutrient utilized by the thyroid glands, and deficiency of this element has been linked to reproductive failures. Iodide transporters are also present in reproductive tissues and cells of embryonic origin such as the endometrium and trophoblasts, respectively. The aim of this study is to understand if levels of iodide transporters are linked to pregnancy outcomes. Subjects and Methods: RNA derived from endometrial biopsies from controls or women with recurrent reproductive failures was analyzed utilizing RT-PCR and targeted RNASeq. Results: When compared to controls, women with 2 or more reproductive failures had a significant increase (>5 fold) in mRNA levels of the iodine transporters NIS and PENDRIN, but not thyroglobulin when probed vis RT-PCR. Targeted RNASeq analysis confirmed these findings when another group of patients were analyzed. Conclusion: These findings suggest possible abnormal iodine metabolism and a deficiency of iodine in endometrial tissues from some of the women with reproductive failures. We hypothesize from these findings that inorganic iodide and/or iodine is required for optimal cellular function in reproductive tissues, and that iodide transporters may potentially be used as a marker for infertility or for probing potential localized iodine deficiency that may not present in a typical thyroid panel analysis.

2649 A Case of Primary Intestinal Lymphangiectasia in an African American Adult Male With Intermittent Abdominal Pain and Diarrhea

INTRODUCTION: Primary intestinal lymphangiectasia is a rare type of protein losing enteropathy in which there is a localized or diffuse ectasia of the enteric lymphatic causing leakage of protein into the intestinal lumen. Here, we describe a case of Primary Intestinal Lymphangeictasia in a patient presenting with chronic intermittent abdominal pain and diarrhea. CASE DESCRIPTION/METHODS: Patient is a 56-year-old African-American male with history of COPD, DM, morbid obesity, GERD who presented to our office as a referral after hospitalization for for evaluation of abdominal pain and diarrhea. Patient was hospitalized for 3 day duration of epigastric pain and watery diarrhea. There, he was noted to have hypocalcemia, hypoalbuminemia, and trace urine proteinuria. Lactate was normal. CT abdomen pelvis showed nonspecific Jujenitis. He was treated empirically with Intravenous antibiotics and discharged home. During follow up visits, initial comprehensive workup for inflammatory bowel disease, celiac disease, stool pathogens, thyroid panel, lipid panel, Alpha-1-Antitrypsin stool clearance, and HIV were all unremarkable. Patient subsequently underwent colonoscopy and EGD. Colonoscopy revealed sigmoid diverticulosis and internal hemorrhoids. EGD revealed nonspecific jejunitis. He had yet another hospitalization for worsening similar acute abdominal pain. During his second hospitalization, labs showed mild leukocytosis, CT abdomen and pelvis revealed jejunal edema. He was taken for diagnostic laparoscopy which only showed mild ascites and thickening of the jejunum. Surgical pathology unfortunately was inconclusive. Patient followed up again as an outpatient and underwent small capsule endoscopy which revealed lymphangiectasia at the jejunum. Patient was referred to a dietitian where he was placed on high protein and Medium chain triglycerides diet. DISCUSSION: Primary Intestinal Lymphangeictasia is a rare cause of protein losing enteropathy that can manifest as non-specific abdominal pain and diarrhea. In this case, the patient had chronic intermittent abdominal pain and diarrhea which required capsule endoscopy in order to diagnose and was missed on surgical pathology. Much like an Inflammatory Bowel disease which can take several studies and biopsies in order to diagnose, albeit different pathophysiology, Primary intestinal lymphaniectasia is a rare cause of abdominal pain that should be on the differential when evaluating chronic intermittent severe abdominal pain and diarrhea of unknown etiology.

Radiation-Related Toxicities Using Organ Sparing Total Marrow Irradiation Transplant Conditioning Regimens

Toxicities after organ sparing myeloablative total marrow irradiation (TMI) conditioning regimens have not been well characterized. The purpose of this study is to report pulmonary, renal, thyroid, and cataract toxicities from a prospective trial monitoring patients up to 8 years after TMI. A total of 142 patients with primarily multiple myeloma or acute leukemia undergoing hematopoietic cell transplantation were evaluated. Follow-up included pulmonary function tests, serum creatinine, glomerular filtration rate, thyroid panel, and ophthalmologic examinations performed at 100 days, 6 months, and annually. Median TMI dose was 14 Gy (10-19 Gy) delivered at 1.5 to 2.0 Gy twice per day at a dose-rate of 200 cGy/min. Median age was 52 years (range 9-70). Median follow-up (range) for all patients was 2 years (0-8) and for patients alive at the time of last follow-up (n = 50), 5.5 years (0-8). Mean organ doses in Gy were lung 7.0, kidneys 7.1, thyroid 6.7, and lens 2.8. The crude incidence of radiation pneumonitis (RP) was 1 of 142 (0.7%). The cumulative incidence of infection and RP (I/RP) was 22.7% at 2 years post-TMI. Mean lung dose ≤8 Gy predicted for significantly lower rates of I/RP (2-year cumulative incidence 20.8% vs 31.8%, P = .012). No radiation-induced renal toxicity was noted. Hypothyroidism occurred in 6.0% and cataract formation in 7.0% of patients. TMI delivered with intensity modulated radiation therapy results in lower organ doses and was associated with fewer toxicities compared with historical cohorts treated with conventional total body irradiation. Keeping the mean lung dose to 8 Gy or less was associated with lower pulmonary complications. Further evaluation in clinical trials of intensity modulated radiation therapy to deliver TMI, total marrow and lymphoid irradiation, and organ sparing conformal total body irradiation is warranted.

Comparison of in Situ and Extraction-Based Methods for the Detection of ROS1 Rearrangements in Solid Tumors

Clinical data confirmed that patients with ROS1 rearrangement are sensitive to specific inhibitors. Therefore, reliable detection of ROS1 rearrangements is essential. Several diagnostic techniques are currently available. However, previous studies were hampered by the low number of ROS1-positive samples. Thirty-five samples, including 32 ROS1 fluorescent in situ hybridization (FISH)-positive and three ROS1 FISH-negative samples were evaluated by ROS1 chromogenic in situ hybridization, ROS proto-oncogene 1, receptor tyrosine kinase (ROS1) immunohistochemistry (IHC), an Agilent SureSelectXT HS custom panel, the Archer FusionPlex Comprehensive Thyroid and Lung panel, and a custom NanoString fusion panel. Some samples were additionally analyzed with the Illumina TruSight Tumor 170 assay. Eleven samples were ROS1 FISH positive by a break-apart signal pattern. In all 11 samples, a ROS1 fusion was confirmed by at least one other method. The other 21 samples tested ROS1 FISH positive by an isolated 3' green signal pattern. Ten of 21 samples could be confirmed by at least two other methods. The other 11 samples tested negative by ROS1 IHC and at least one other method, indicating a false-positive ROS1 FISH result. Our study found that all ROS1 FISH-positive samples with isolated 3' green signals should be confirmed by another method. When sufficient material is available, extraction-based parallel sequencing approaches for the verification of these cases might be preferable.

SUN-551 Massive Pericardial Effusion Complicating Systemic Lupus Erythematosus and Autoimmune Hypothyroidism: A Case Report

Background: The presence of autoantibodies is a mutual ground for Systemic Lupus Erythematosus (SLE) and Autoimmune Hypothyroidism (AH). Pericardial effusion (PEEF) is a common manifestation for each disease condition however massive PEEF especially with tamponade is a rare occurrence. The coexistence of SLE and AH causing massive PEEF is even rarer and only few cases have been reported. This presents as a diagnostic dilemma whether the massive PEEF is primarily driven by SLE, AH or is it a synergistic effect of both. Clinical Case: A case of a 54-year-old female, hypertensive, non-diabetic diagnosed previously with primary hypothyroidism came in with progressive dyspnea. She has been non-compliant to levothyroxine therapy for 1 year. Upon presentation at the Emergency Department, she was noted to be overtly hypothyroid. Thyroid panel was consistent with primary AH: elevated TSH = 95.66 uIU/mL (NV=0.35-4.94), low FT3 = <1 pg/mL (NV=1.71-3.71), low FT4 = <0.4 ng/dL (NV=0.7-1.48) and elevated anti-TPO = 770.9 IU/mL (NV=<9.0). Ultrasound of the thyroid showed non-uniform echopattern. Pertinent physical findings were an elevated JVP and muffled heart sounds but with stable blood pressure. A 2-dimensional echocardiogram (2D-Echo) confirmed the presence of massive PEEF with doppler evidence of beginning tamponade. Other laboratory findings were anemia, leukopenia, albuminuria and high creatinine level. With this unusual clinical presentation, SLE as a secondary cause of PEEF was entertained. ANA at 1:320 with speckled pattern as well as anti-dsDNA at 516.25 IU/ml (NV=<0-200) were both positive with low complement factor 3 level (C3) = 0.89 g/L (NV=0.9-1.8) fulfilling the Systemic Lupus International Collaborating Clinics (SLICC) criteria for SLE. The patient was given levothyroxine and prednisone for primary hypothyroidism and SLE, respectively. There was then gradual improvement of symptoms with a decrease in the PEEF on repeat 2D-Echo. She was noted to be clinically stable on subsequent follow-ups with further resolution of the massive PEEF. Conclusion: This was a rare case of SLE and AH causing massive PEEF with beginning tamponade which was successfully managed medically. This gave us valuable insight that massive PEEF occurring in hypothyroidism may be secondarily caused by other co-existing disease entities. Although it remained to be a diagnostic dilemma whether the massive PEEF was primarily because of SLE or AH or an effect of both, this case offered another opportunity to further explore the relationship of AH and connective tissue diseases such as SLE.